Table 3.

Prevalence of CKD stages 1 through 4 in Norway and the United Statesa

CKD StageNorwayUnited States
1995 to 19971988 to 19941999 to 2000
White(n = 65,181)bWhite(n = 6635)Black(n = 4163)Overall(n = 15,625)Overall(n= 4104)
12.7 (0.3)2.8 (0.3)5.8 (0.3)3.3 (0.3)3.8 (0.5)
23.2 (0.4)3.2 (0.3)2.5 (0.3)3.0 (0.3)4.0 (0.5)
34.2 (0.1)4.8 (0.3)3.1 (0.2)4.3 (0.3)3.7 (0.4)
40.16 (0.01)0.21 (0.03)0.25 (0.08)0.20 (0.03)0.13 (0.06)
Total10.2 (0.5)11.0 (0.6)11.6 (0.5)11.0 (0.5)11.7 (0.8)
  • a Data are % (SE). CKD stages 1 to 2 are estimated using gender-specific ACR cutoffs (17 to 250 mg/g [1.9 to 28.3 mg/mmol] for men and 25 to 355 mg/g [2.8 to 40.2 mg/mmol] for women). The prevalence using 30 to 300 mg/g (3.4 to 34.0 mg/mmol) for both men and women for stages 1 through 4 and total are as follows: 1.6, 2.2, 4.2, 0.16, and 8.0 for Norway and 1.8, 2.2, 4.8, 0.2, and 9.0 for US white patients in 1988 through 1994 and 2.8, 2.8, 3.7, 0.13, and 9.4 for US patients in 1999 through 2000.

  • b Data from the HUNT II study were age and gender standardized to the Norwegian 1996 population. When the data were age and gender standardized to the US 1991 population, CKD prevalence was 9.3% (2.6, 2.9, 3.7, and 0.14% for stages 1 through 4, respectively).